BioXcel Therapeutics (BTAI) Reports Q4 Loss of $0.87/sh

BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($0.87), versus ($0.45) reported last year.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• BMO starts chip stocks coverage: Here are its preferred picks